675 related articles for article (PubMed ID: 15038217)
21. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy.
Shaked Y; Kerbel RS
Cancer Res; 2007 Aug; 67(15):7055-8. PubMed ID: 17671170
[TBL] [Abstract][Full Text] [Related]
22. Role of hematopoietic lineage cells as accessory components in blood vessel formation.
Takakura N
Cancer Sci; 2006 Jul; 97(7):568-74. PubMed ID: 16827795
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis as a therapeutic target.
Ferrara N; Kerbel RS
Nature; 2005 Dec; 438(7070):967-74. PubMed ID: 16355214
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Kerbel RS
Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies.
Pluda JM
Semin Oncol; 1997 Apr; 24(2):203-18. PubMed ID: 9129690
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis inhibitors in cancer therapy.
Dredge K; Dalgleish AG; Marriott JB
Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
[TBL] [Abstract][Full Text] [Related]
27. Endostatin: the logic of antiangiogenic therapy.
Abdollahi A; Hlatky L; Huber PE
Drug Resist Updat; 2005; 8(1-2):59-74. PubMed ID: 15939343
[TBL] [Abstract][Full Text] [Related]
28. The combination of antiangiogenic therapy with other modalities.
O'Reilly MS
Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
[TBL] [Abstract][Full Text] [Related]
29. [Targeting angiogenesis in oncology].
Fayette J; Soria JC; Armand JP
Pathol Biol (Paris); 2006 May; 54(4):199-205. PubMed ID: 16753494
[TBL] [Abstract][Full Text] [Related]
30. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
31. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
Osada H; Kakeya H
Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of angiogenesis.
Folkman J; Ingber D
Semin Cancer Biol; 1992 Apr; 3(2):89-96. PubMed ID: 1378314
[TBL] [Abstract][Full Text] [Related]
33. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of angiogenesis in the treatment of tumors.
Ostrowski K; Kinsner A
Arch Immunol Ther Exp (Warsz); 2001; 49(1):27-31. PubMed ID: 11266087
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Folkman J
Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
[TBL] [Abstract][Full Text] [Related]
36. Platelets and cancer: implications for antiangiogenic therapy.
Trikha M; Nakada MT
Semin Thromb Hemost; 2002 Feb; 28(1):39-44. PubMed ID: 11885024
[TBL] [Abstract][Full Text] [Related]
37. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.
Cao Y; Zhong W; Sun Y
Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151
[TBL] [Abstract][Full Text] [Related]
38. A surrogate marker to monitor angiogenesis at last.
Schneider M; Tjwa M; Carmeliet P
Cancer Cell; 2005 Jan; 7(1):3-4. PubMed ID: 15652744
[TBL] [Abstract][Full Text] [Related]
39. Optical imaging and tumor angiogenesis.
Lin PC
J Cell Biochem; 2003 Oct; 90(3):484-91. PubMed ID: 14523982
[TBL] [Abstract][Full Text] [Related]
40. Tumoral angiogenesis: review of the literature.
Khosravi Shahi P; Fernández Pineda I
Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
